Catalyst Wire Dossier Catalyst Wire Dossier

Fovista

E10030 · Ophthotech Corporation
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Fovista, covering 2018-08-10 to 2020-09-30. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy [Phase 3]

See pricing